Reviewer's report

Title: Review of risk sharing schemes for pharmaceuticals: considerations, critical evaluation and recommendations for European payers

Version: 1 Date: 28 February 2010

Reviewer: Anna Birna Almarsdóttir

Reviewer's report:

This manuscript was a very interesting read, well organised and thorough. I recommend it be published without any significant Major Compulsory Revisions. There are a couple of issues that can easily be dealt with:

The difference between PVA and price caps in not entirely clear and a sentence or two to explain would be good to add on page 3.

Please explain what you mean by learning from procurement. I am not clear on how and what is to be learnt.

Minor Essential Revisions:

Explain on p.10 what is meant by "the two different schemes" (middle of the page).

Typos on p. 11: "... are not taken as recommended." and "... members who have previously been poor compliers..." (middle of the page).

Write Primary Care Trusts (PCTs) in stead of just the acronym.

Discretionary Revisions

Table 1: The authors suggest that this table can be put in an appendix. If this is done, then there needs to be text to explain broadly what the examples entail. I find all the tables very informative.

Level of interest: An article of importance in its field

Quality of written English: Acceptable

Statistical review: No, the manuscript does not need to be seen by a statistician.

Declaration of competing interests:

I declare that I have no competing interests